Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 18/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 9/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 7/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359268 | 1.00 | NTRK1 (0.45) | NTRK1NTRK3NTRK2MKNK2PCSK9 | |
| SCHEMBL20359267 | 1.00 | NTRK1 (0.45) | NTRK1NTRK3NTRK2MKNK2PCSK9 | |
| SCHEMBL31250788 | 0.94 | NTRK1 (0.44) | NTRK1NTRK3NTRK2PCSK9 | |
| SCHEMBL20371088 | 0.92 | NTRK1 (0.46) | NTRK1NTRK3NTRK2MKNK2PCSK9 | |
| SCHEMBL20359956 | 0.92 | NTRK1 (0.43) | NTRK1NTRK3NTRK2MKNK2 | |
| SCHEMBL20359954 | 0.92 | NTRK1 (0.43) | NTRK1NTRK3NTRK2MKNK2 | |
| SCHEMBL21815180 | 0.92 | NTRK1 (0.43) | NTRK1NTRK3NTRK2MKNK2 | |
| SCHEMBL16946813 | 0.92 | NTRK1 (0.43) | NTRK1NTRK3NTRK2MKNK2 | |
| SCHEMBL23083841 | 0.91 | NTRK1 (0.45) | NTRK1NTRK3NTRK2MKNK2PCSK9 | |
| SCHEMBL26108651 | 0.88 | PCSK9 (0.43) | NTRK1NTRK3NTRK2MKNK2PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375451-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | TURNING POINT THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250223298-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-12310968-B2 | Chiral diaryl macrocycles and uses thereof | Turning Point Therapeutics, Inc. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12187739-B2 | Diaryl macrocycle polymorph | Turning Point Therapeutics, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4480543-A2 | CHIRAL DIARYL MACROCYCLE AND USE THEREOF IN THE TREATMENT OF CANCER | Turning Point Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3733187-B1 | CHIRAL DIARYL MACROCYCLE AND USE THEREOF IN THE TREATMENT OF CANCER | TURNING POINT THERAPEUTICS INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4397665-A2 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4397665-A2 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3319969-B1 | DIARYL MACROCYCLE POLYMORPH | TURNING POINT THERAPEUTICS INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20230346786-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | Turning Point Therapeutics, Inc. | 2023-11-02 | — | — | US | disclosed |
| EP-3325488-B1 | CHIRAL DIARYL MACROCYCLE AND USE THEREOF IN THE TREATMENT OF CANCER | TURNING POINT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190233437-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2019-08-01 | — | — | US | disclosed |
| US-20190233437-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2019-08-01 | — | — | US | disclosed |
| US-10294242-B2 | Diaryl macrocycle polymorph | TP THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294242-B2 | Diaryl macrocycle polymorph | TP THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180325901-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | Turning Point Therapeutics, Inc. | 2018-11-15 | — | — | US | disclosed |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2018-07-12 | — | — | US | disclosed |
| WO-2017007759-A1 | DIARYL MACROCYCLE POLYMORPH | TP THERAPEUTICS, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325901-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | PKD1, DHCR7, PKD2 | NTRK1 4685/4885NTRK3 3988/4885NTRK2 3866/4885 |
| US-20250375451-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | PKD1, PKD2, CYP7B1 | NTRK1 4765/4885NTRK3 4444/4885NTRK2 4042/4885 |
| US-12310968-B2 | Chiral diaryl macrocycles and uses thereof | PKD1, DHCR7, PKD2 | NTRK1 4685/4885NTRK3 3988/4885NTRK2 3866/4885 |
| US-10294242-B2 | Diaryl macrocycle polymorph | PKD1, CYP7B1, BRCA1 | NTRK1 4846/4885NTRK3 4843/4885NTRK2 4861/4885 |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | NTRK1 4846/4885NTRK3 4843/4885NTRK2 4861/4885 |
| US-20190233437-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | NTRK1 4846/4885NTRK3 4843/4885NTRK2 4861/4885 |
| US-20230346786-A1 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | PKD1, DHCR7, PKD2 | NTRK1 4685/4885NTRK3 3988/4885NTRK2 3866/4885 |
| US-12187739-B2 | Diaryl macrocycle polymorph | PKD1, CYP7B1, BRCA1 | NTRK1 4846/4885NTRK3 4843/4885NTRK2 4861/4885 |
| US-20250223298-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | NTRK1 4846/4885NTRK3 4843/4885NTRK2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.